[Oltipraz as brief treatment of schistosomiasis (comparison with niridazole) (author's transl)].
161 patients affected by schistosomiasis due in most cases to S. haematobium, and less frequently to S. mansoni, received one day treatment with 4,5 g a day of oltipraz in a first group and, later on, 3 g a day in another group. A control after one year was possible for patients having received 4,5 g one day dosis. Urin control, rectal mucosa biopsy (R.M.B.) and indirect immunofluorescence test (I.I.F.) were performed in patients who did not return to infested areas during that period of time; in almost all cases, the urin control was negative; in 52 p. 100 of the cases the R.M.B. shown no live egg and I.I.F. test was significantly decreased with individual variations. -- These results are compared to those of a previous and similar study on the effects of niridazole. -- Side-effects, mostly digestive or nervous, are frequent with a 4,5 g dose and less frequent with 3 g. They rarely compel to discard the treatment and they never persist after the morning following the treatment is stopped. There is no electrocardiographic change. -- Doses below 3 g in one-day intake are presently studied in order to fix the minimal acting dosis.